Crispr Therapeutics AG vs TJX Companies Inc — how do they compare? Crispr Therapeutics AG trades at $50.7 (market cap $4.97B), while TJX Companies Inc trades at $150.59 (market cap $166.08B). The key difference: TJX Companies Inc is far larger — about 33.4× Crispr Therapeutics AG's market cap, and TJX Companies Inc pays a 1.28% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TJX | |
|---|---|---|
Market Cap | $4.97B | $166.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $168.41 |
52-Week Low | $44.34 | $121.35 |
Enterprise Value | $3.32B | $174.68B |
Dividend Yield | — | 1.28% |
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
TJX trades at $150.53, down 0.54% today, with strong fundamentals including 8.63% net margin and 61.25% ROE. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Technical indicators signal near-term bearish pressure, but analyst consensus remains overwhelmingly bullish with an $181.80 price target. The company maintains robust cash flow from operations at $6.12B in 2025, supporting dividend payments and expansion plans.
Outlook is positive due to earnings momentum and international growth, but risks include valuation premiums (P/E 29.29) and consumer spending sensitivity. The stock offers growth potential if execution continues, though technical weakness may persist short-term.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →